TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01435707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: epidural steroid injection with Triamcinolone 40mg
Description: epidural steroid injection with Triamcinolone 40mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selective transforaminal epidural block with triamcinolone 20 mg
Description: Selective transforaminal epidural block with triamcinolone 20 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caudal epidural steroid injection with Triamcinolone 20mg
Description: caudal epidural steroid injection with Triamcinolone 20mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selective transforaminal epidural block with triamcinolone 40 mg
Description: Selective transforaminal epidural block with triamcinolone 40 mg
Study: NCT04248907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0 pound tension
Description: A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2 pound tension
Description: A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4 pound tension
Description: A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
Study: NCT00517049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO95780
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose
Study: NCT01954433

Intervention type: PROCEDURE
Intervention: Operated TSA Patients
Description: Total shoulder prosthesis: Anatomic or reverse total shoulder replacement is a well-standardized procedure usually performed under general anesthesia with the patient in a beach-chair position

Intervention type: PROCEDURE
Intervention: Operated RCR Patients
Description: Arthroscopic rotator cuff tear reconstruction. The shoulder arthroscopy is performed according to internal and international standard procedure with patients positioned in beach-chair position under general anesthesia.

Intervention type: PROCEDURE
Intervention: Resection interposition suspension arthroplasty (RISA)
Description: One of five surgical techniques can be used in this study, as routinely performed by each surgeon:~1. RISA with FCR-Ligament (flexor carpi radialis ligament) modified according to Epping~2. RISA with FCR-Ligament modified according to Weilby~3. RISA with APL-Ligament (abductor pollicis longus ligament)~4. RISA with Graftjacket modified according to Weilby~5. Resection arthroplasty
Study: NCT04546802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elbasvir / Grazoprevir Oral Tablet
Description: Elbasvir / Grazoprevir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elbasvir / Grazoprevir Oral Tablet
Description: Elbasvir / Grazoprevir
Study: NCT03135106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: A single 4-mg of erdafitinib tablet will be administered on Day 1 in Treatment A and on Day 5 in Treatment B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: A single 4-mg of erdafitinib tablet will be administered on Day 1 in Treatment A and on Day 5 in Treatment B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: A single 4-mg of erdafitinib tablet will be administered on Day 1 in Treatment A and on Day 5 in Treatment B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: A 400-mg fluconazole orally (4\*100 mg capsules) will be administered from Day 1 to Day 11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: A 200-mg itraconazole orally (2\*100 mg capsules) will be administered from Day 1 to Day 11.
Study: NCT01114451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of surgical skin staples
Description: Skin staples will be removed using standard technique with subsequent placement of steri-trips

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of surgical skin staples
Description: Skin staples will be removed using standard technique with subsequent placement of steri-trips
Study: NCT01165177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster Vaccine GSK1437173A
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study: NCT02162498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feeding buddies
Description: The Window of Opportunity program is implementing feeding buddies within their comprehensive programming. Their feeding buddies intervention targets all mothers at ANC for promoting health behaviors, especially exclusive breastfeeding.~The NIH study is an implementation science award to evaluate the feeding buddies intervention, specifically among HIV positive recipients and evaluating the outcome of adherence to PMTCT recommendations.
Study: NCT00781937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide 3.0 mg per day administered in a 6.0 mg/mL, 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
Study: NCT00216047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787
Description: PTK787 daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 4 mg/kg IV week 1, followed by 2 mg/kg weekly with disease evaluation every other cycle\*
Study: NCT01263249

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Anterior to the Femoral Nerve
Description: Extremity randomized to Anterior Placement will be given a peripheral nerve block with the catheter placed just anterior to the femoral nerve. 4cc of Ropivicaine will be administered continuously every hour by a pain pain pump and the outcome measures will be tested.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Posterior to the Femoral Nerve
Description: Extremity randomized to Posterior Placement will be given a peripheral nerve block with the catheter placed just posterior to the femoral nerve. 4cc of Ropivicaine will be administered continuously every hour by a pain pain pump and the outcome measures will be tested.
Study: NCT00013611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin
Description: Recombinant IL-2 was given at a dose of 4.5 MIU twice daily subcutaneously for 5 consecutive days every 8 weeks, in addition to antiretroviral therapy, for 6 cycles. After the first 6 cycles, additional cycles were given to either achieve or maintain the patient's CD4+ cell count goal.
Study: NCT03814304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized tDCS
Description: The participant will receive 20, 20-minute sessions of personalized tDCS on Monday-Friday, at approximately the same time of day, over four consecutive weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Active-Sham
Description: The participant will receive 20, 20-minute sessions of active-sham stimulation on Monday-Friday, at approximately the same time of day, over four consecutive weeks.
Study: NCT01150045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Patients receive celecoxib 400 mg administered by mouth, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Patients receive celecoxib 400 mg administered by mouth, once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Patients receive 400 mg/m\^2 intravenous bolus then 2400 mg/m\^2 continuous intravenous infusion over 46-48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Patients receive 400 mg/m\^2 intravenous bolus then 2400 mg/m\^2 continuous intravenous infusion over 46-48 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Patients receive 400 mg/m\^2 intravenous bolus then 2400 mg/m\^2 continuous intravenous infusion over 46-48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Patients receive 400 mg/m\^2 intravenous bolus then 2400 mg/m\^2 continuous intravenous infusion over 46-48 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Patients receive placebo administered by mouth, once daily.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Patients receive placebo administered by mouth, once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Patients receive 85 mg/m\^2 intravenous over two hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Patients receive 85 mg/m\^2 intravenous over two hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Patients receive 85 mg/m\^2 intravenous over two hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Patients receive 85 mg/m\^2 intravenous over two hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin
Description: Patients receive 400 mg/m\^2 intravenous over two hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Patients receive 400 mg/m\^2 intravenous over two hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin
Description: Patients receive 400 mg/m\^2 intravenous over two hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Patients receive 400 mg/m\^2 intravenous over two hours.
Study: NCT03194867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT01438385

Intervention type: PROCEDURE
Intervention: Interventional Endoscopy
Description: Advanced imaging endoscopic or therapeutic endoscopy
Study: NCT00939237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ateronon
Description: 7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03489902

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transobturator Paravaginal Repair
Description: Transobturator application of sutures to the white line in cases needing paravaginal repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traditional transvaginal Paravaginal Repair
Description: traditional transvaginal application of sutures to the white line
Study: NCT02547701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-3058
Study: NCT03472001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflection and feedback
Description: 2-hour training involving 10 written clinical cases to encourage students to practice thinking like a dermatologist in their clinical reasoning, and to help students build adequate illness scripts of skin diseases
Study: NCT03194867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab REGN2810
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab REGN2810
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT00543062

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo
Description: Inhaled Staccato placebo (0 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo
Description: Inhaled Staccato placebo (0 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo
Description: Inhaled Staccato placebo (0 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo
Description: Inhaled Staccato placebo (0 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo
Description: Oral placebo (identical to 400 mg moxifloxacin)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo
Description: Oral placebo (identical to 400 mg moxifloxacin)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo
Description: Oral placebo (identical to 400 mg moxifloxacin)

Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo
Description: Oral placebo (identical to 400 mg moxifloxacin)

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled prochlorperazine 5 mg
Description: Staccato prochlorperazine 5 mg, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled prochlorperazine 5 mg
Description: Staccato prochlorperazine 5 mg, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled prochlorperazine 5 mg
Description: Staccato prochlorperazine 5 mg, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled prochlorperazine 5 mg
Description: Staccato prochlorperazine 5 mg, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled prochlorperazine 10 mg
Description: Inhaled prochlorperazine 10 mg, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled prochlorperazine 10 mg
Description: Inhaled prochlorperazine 10 mg, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled prochlorperazine 10 mg
Description: Inhaled prochlorperazine 10 mg, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled prochlorperazine 10 mg
Description: Inhaled prochlorperazine 10 mg, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Oral moxifloxacin
Description: Oral moxifloxacin 400 mg, si/ngle dose

Intervention type: DRUG
Group type: OTHER
Intervention: Oral moxifloxacin
Description: Oral moxifloxacin 400 mg, si/ngle dose

Intervention type: DRUG
Group type: OTHER
Intervention: Oral moxifloxacin
Description: Oral moxifloxacin 400 mg, si/ngle dose

Intervention type: DRUG
Group type: OTHER
Intervention: Oral moxifloxacin
Description: Oral moxifloxacin 400 mg, si/ngle dose
Study: NCT00464945

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: 1 dose at 2,3,4 and 12 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: 1 dose at 2,3,4 and 12 months of age
Study: NCT00003058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: troglitazone
Study: NCT03472001

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lecture
Description: Traditional didactic lecture which uses the same clinical cases
Study: NCT00109941

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: opioid growth factor
Description: OGF was administered in saline at 250 ug/kg intravenously over 45 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: metenkephalin, OGF-opioid growth factor
Description: OGF given in saline iv 250 ug/kg weekly
Study: NCT03141034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: -Irinotecan is commercially available and will be billed to insurance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: -Ramucirumab will be provided free of charge by Eli Lilly and Company.
Study: NCT04025268

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Prenatal Care (GPNC)
Description: GPNC participants will attend 11 group sessions total: 10 during pregnancy and one postpartum. Each session will be 90-100 minutes long. Groups will collectively identify the preferred time of day for these sessions. Groups of 10 women will be led by a locally trained, Samoan nurse-midwife with the study Project Director as a co-facilitator. At each of the visits participants will engage in self-assessments of weight and blood pressure, including learning to take their blood pressure with a digital cuff, calculating BMI, and plotting their weight gain on a graph), receive short individual clinical examinations from a midwife, and participate in group discussions about prenatal care, childbirth preparation, and their postpartum care. The session at 6-weeks postpartum will allow women to introduce their babies to the group and share childbirth stories.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of prenatal care
Study: NCT04253847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical antegrade modular pancreatosplenectomy
Description: Radical antegrade modular pancreatosplenectomy (RAMPS) includes the following aspects. Firstly, the surgical approach is antegrade, which means from the right to the left, the pancreatic neck will be transected at first and the spleen will be seperated at last. Secondly, lymph nodes dissection includes not only the regional lymph nodes(No.10,11,18 lymph nodes), but also N1 station lymph nodes (N1: 6, 8a, 8p, 12a2/b2/p2, 13a/b, 14b/c/d, 14v, 17a/b), No.7, 9 lymph nodes, the lymph nodes anterior and left of superior mesenteric artery, as well as the peripheral nerve of celiac trunk. Thirdly, the transection platform is in the pancreatic neck, which is mandatory. At last, left prerenal fascia will be resected. When the tumor abuts or infiltrates the left adrenal gland, left adrenalectomy will be performed, which is also called posterior approach RAMPS. While in normal cases, left adrenal gland will be preserved.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard retrograde pancreatosplenectomy
Description: Standard retrograde pancreatosplenectomy(SRPS) includes several aspects. Firstly, the surgical approach is retrograde, which means from the left to the right, spleen will be seperated at first and the pancreas will be transected later on. Secondly, only the regional lymph nodes will be dissected, which include No.10, No.11, No.18 lymph nodes, and No.9 lymph nodes should be dissected only when the lesion is in pancreatic neck. Thirdly, the transection platform is in the left side of the lesion, but transection at pancreatic neck is not mandatory. At last, the surgical plane is anterior to the left renal fascia, prerenal fascia will be preserved.
Study: NCT02075619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine+Rosuvastatin
Description: Amlodipine 10mg will be supplied as white or off-white, emerald shaped tablet. Rosuvastatin 20mg will be supplied as pink round film coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine+Rosuvastatin
Description: Amlodipine 10mg will be supplied as white or off-white, emerald shaped tablet. Rosuvastatin 20mg will be supplied as pink round film coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine+Rosuvastatin
Description: Amlodipine 10mg will be supplied as white or off-white, emerald shaped tablet. Rosuvastatin 20mg will be supplied as pink round film coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine+Rosuvastatin
Description: Amlodipine 10mg will be supplied as white or off-white, emerald shaped tablet. Rosuvastatin 20mg will be supplied as pink round film coated tablet.
Study: NCT03141034

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood for angiome profiling
Description: -Before treatment on cycle 1 day 1, cycle 5 day 1, cycle 9 day 1, and end of treatment

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood for cfDNA
Description: -Before treatment on cycle 1 day 1, cycle 3 day 1, cycle 5 day 1, cycle 7 day 1, cycle 9 day 1, and end of treatment
Study: NCT03592784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Order Therapy
Description: Instructing patient to, whenever possible, eat carbohydrates at the end of their meal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Nutrition Therapy
Description: Key components of this therapy include counseling to incorporate portion control, increased intake of vegetables and low glycemic index carbohydrates, and mild carbohydrate restriction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Nutrition Therapy
Description: Key components of this therapy include counseling to incorporate portion control, increased intake of vegetables and low glycemic index carbohydrates, and mild carbohydrate restriction.
Study: NCT02547896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codeine + Diclofenac
Description: The patients will receive codeine and diclofenac as pain relief medicine after the surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: The patients will receive only diclofenac
Study: NCT02314312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus + low dose cyclosporin A + prednisolone

Intervention type: DRUG
Group type: OTHER
Intervention: Standard immunosupressive regimen
Study: NCT01370616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem sodium
Description: Ertapenem sodium, 1.0 g IV daily over 30 minutes at Hour 0 for 5 to 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/tazobactam sodium
Description: Piperacillin/tazobactam sodium, 4.5 g, IV every 8 hours, given over 30 minutes at Hours 0, 8, and 16 for 5 to 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam-matching placebo
Description: Placebo, IV over 30 minutes, 2 times per day at Hours 8 and 16 for 5 to 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulunate potassium
Description: If clinically indicated, participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/clavulunate potassium
Description: If clinically indicated, participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28